Core Points - The Shanghai Composite Index closed at 3822.59 points, above the six-month moving average, with a slight increase of 0.07% [1] - The total trading volume of A-shares reached 13556.41 billion yuan, indicating active market participation [1] - A total of 49 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3822.59 points, reflecting a 0.07% increase [1] - The total trading volume for A-shares today is 13556.41 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 49 A-shares have broken through the six-month moving average [1] - Stocks with the highest deviation rates include: - Shengyuan Environmental Protection: 6.76% - Zhixin Electronics: 6.18% - Weixing Intelligent: 6.16% [1] Additional Stock Information - Other stocks that have recently crossed the six-month line with lower deviation rates include: - Shuanglu Pharmaceutical - China Merchants Jiyu - Libote [1]

证券日报网讯9月10日晚间，合富中国（603122）发布公告称，公司2025年1月份至8月份合并营业收入 人民币48，588.47万元，较去年同期下降21.93%，2025年1月份至7月份合并营业收入较去年同期下降 22.66%，下降幅度收窄0.73%，营收情况持续改善。 ...

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

2025 年 1-8 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn）上披露本公司 营业收入。本简报为初步核算数据，未经会计师事务所审计或审阅，最终数据 以公司定期报告为准，敬请投资者注意投资风险。 公司 2025 年 1-8 月合并营业收入人民币 48,588.47 万元，较去年同期下降 21.93%，2025 年 1-7 月合并营业收入较去年同期下降 22.66%，下降幅度收窄 0.73%，营收情况持续改善。 证券代码：603122 证券简称：合富中国 公告编号：临 2025 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

智通财经APP讯，合富中国(603122.SH)发布公告，1-8月合并营业收入人民币4.86亿元，较去年同期下 降21.93%，1-7月合并营业收入较去年同期下降22.66%，下降幅度收窄0.73%，营收情况持续改善。 ...

人民财讯9月10日电，合富中国（603122）9月10日晚间公告，公司1—8月合并营业收入4.86亿元，较去 年同期下降21.93%，1—7月合并营业收入较去年同期下降22.66%，下降幅度收窄0.73%，营收情况持续 改善。 ...

合富中国（603122）(603122.SH)发布公告，1-8月合并营业收入人民币4.86亿元，较去年同期下降 21.93%，1-7月合并营业收入较去年同期下降22.66%，下降幅度收窄0.73%，营收情况持续改善。 ...

合富中国公告，公司2025年1-8月合并营业收入4.86亿元，较去年同期下降21.93%；2025年1-7月合并营 业收入较去年同期下降22.66%，下降幅度收窄0.73%，营收情况持续改善。 ...

格隆汇9月10日丨合富中国(603122.SH)公布，公司2025年1-8月合并营业收入人民币4.86亿元，较去年同 期下降21.93%，2025年1-7月合并营业收入较去年同期下降22.66%，下降幅度收窄0.73%，营收情况持 续改善。 ...